U.S. FDA panel votes against approval of Nektar's opioid painkiller

Independent advisers to the U.S. Food and Drug Administration on Tuesday unanimously voted against Nektar Therapeutics' opioid painkiller for adults with chronic low back pain, sending the drug developer's shares down 12% in extended trading.